---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-028274"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T05:11:31.831594+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Humacyte prices 25M-share public offering at $2.00/share, expects $50M gross proceeds

## Summary
- Offering of 25,000,000 shares at $2.00/share; gross proceeds ~$50M, net ~$46.6M after discounts and expenses.
- Underwriters have 30-day option to purchase up to an additional 3,750,000 shares at the same price.
- Proceeds to fund SYMVESS commercialization in vascular trauma, pipeline development, and working capital.
- Expected to close on March 27, 2025; TD Cowen, Barclays, and BTIG are joint book-running managers.

## SEC filing metadata
- accession: 0001104659-25-028274
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465925028274/0001104659-25-028274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465925028274/tm2510460d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-028274
- JSON: https://secwatch.observer/filing/0001104659-25-028274.json
- Plain text: https://secwatch.observer/filing/0001104659-25-028274.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.